Rockefeller Capital Management
ABUS icon

Rockefeller Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Rockefeller Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$284K Hold
63,000
– – ﹤0.01% 2288
2025
Q4 		$303K Hold
63,000
– – ﹤0.01% 2154
2025
Q3 		$286K Buy
+63,000
New +$231K ﹤0.01% 2044
2025
Q2 		– Sell
-63,000
Closed -$220K – 1715
2025
Q1 		$220K Sell
63,000
-43,615
-41% -$145K ﹤0.01% 1643
2024
Q4 		$349K Buy
106,615
+43,615
+69% +$160K ﹤0.01% 1570
2024
Q3 		$243K Buy
+63,000
New +$242K ﹤0.01% 1576

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rockefeller Capital Management's ABUS Position: Q1 2026 in Review

Rockefeller Capital Management held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 63,000 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Rockefeller Capital Management first reported a position in ABUS in Q3 2024 and has held it in 6 quarters since. The position peaked at $349K in Q4 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Rockefeller Capital Management held 63,000 shares of Arbutus Biopharma worth $284K as of Q1 2026.
  • Rockefeller Capital Management left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2288 holding.
  • Rockefeller Capital Management first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 6 quarters since.
  • Rockefeller Capital Management's Arbutus Biopharma position peaked at $349K in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.